Haemato-Onkologie Hamburg - Prof. Laack und Partner

Verified siteinfo

Germany Lehmweg 7, 20251 Hamburg, Germany

2 trials recruiting
Non-small cell lung cancer · Non-small cell lung cancer stage II · Non-small cell lung cancer stage III
Adult patients

About Specializations

Haemato-Onkologie Hamburg - Prof. Laack und Partner in Hamburg, Germany specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer stage II, Non-small cell lung cancer stage III, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms

The Haemato‑Onkologie Hamburg – Prof. Laack und Partner concentrates on cancer research, targeting TROP2‑positive advanced or metastatic non‑squamous non‑small cell lung cancer. Ongoing studies evaluate the safety and efficacy of the antibody‑drug conjugate datopotamab deruxtecan versus standard chemotherapy, with the goal of improving patient outcomes such as progression‑free and overall survival.

Evaluation of a novel antibody‑drug conjugate for lung cancer
Direct comparison with standard docetaxel therapy
Measurement of progression‑free survival and overall survival benefits

With two investigators working at the Hamburg location, the site demonstrates a focused commitment to expanding therapeutic options for patients without actionable genomic alterations.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Lehmweg 720251 HamburgGermany

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 3
Partner status: Verified site

More sites in Hamburg Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

5 clinical trials

Non-small cell lung cancer

Recruiting

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo